Article Text
Miscellaneous
Journal club
Alternatives to warfarin for the treatment of pulmonary emboli: the EINSTEIN-PE Study
Statistics from Altmetric.com
The last few years have seen new oral anticoagulant treatments emerge with a major advantage over conventional vitamin K antagonism with warfarin: they have a predictable dose response that negates the need for laboratory monitoring. Dabigatran (Pradaxa), a direct thrombin inhibitor, and rivaroxaban are two such medications licenced for the prevention of stroke in atrial fibrillation. Rivaroxaban (Xiralto) is a direct inhibitor of Factor Xa. The …
Footnotes
-
Competing interests None.
-
Provenance and peer review Not commissioned; internally peer reviewed.